BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

mRNA company Moderna Inc. (NASDAQ:MRNA) said Elizabeth Nabel has resigned from its board to avoid any potential or apparent conflict of interest. She is president of Brigham and Women’s Hospital, a site enrolling patients in...
BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

An analysis of preclinical IPO performance since the window opened eight years ago shows the companies have done about as well as their clinical peers. What’s missing are standout examples of explosive growth, though those...
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin. FDA’s Oncologic Drugs Advisory Committee unanimously...
BioCentury | Jul 21, 2020
Product Development

Vaccine hopes, the shifting biopharma workplace & Blueprint’s Dx deal: a BioCentury Podcast

New data for the vaccine candidate from Oxford and AstraZeneca have stoked enthusiasm that countermeasures against COVID-19 are within reach. On the latest edition of the BioCentury This Week podcast , BioCentury editors discuss the latest...
BioCentury | Jul 17, 2020
Finance

Data Bytes: preclinical IPO performance trending up

IPOs by preclinical biotechs since 2013 had largely been hit or miss until the past 18 months, when a trend toward positive aftermarket performance has emerged. Sixty percent of the 53 preclinical IPOs on NASDAQ...
BioCentury | Jul 14, 2020
Deals

Roche deal clears path for Blueprint’s financial independence

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...
BioCentury | Jul 10, 2020
Politics, Policy & Law

Democrats, Republicans could find common ground on drug pricing recommendations from Biden-Sanders task force

Recommendations from a task force assembled by Joe Biden and Sen. Bernie Sanders (I-Vt.) include several healthcare policies favored by Democrats, like Medicare drug price negotiation, but stop short of Medicare for All. The bulk...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

Nurix Therapeutics Inc. has announced a slew of leadership changes including Gwenn Hansen’s promotion to CSO from SVP of research, and Hans van Houte’s promotion to CFO from SVP of finance. The targeted protein degradation...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

Targeted degrader company Arvinas takes hit on updated proof of concept data  Arvinas Inc. (NASDAQ:ARVN) shed nearly $500 million in market cap Friday after updated Phase I/II data showed no new responses among 12 additional...
Items per page:
1 - 10 of 442